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Abstract 
OBJECTIVE 
Electronic health records (EHRs) are a promising source of data for health outcomes research in 
oncology. A challenge in using EHR data is that selecting cohorts of patients often requires 
information in unstructured parts of the record. Machine learning has been used to address this, 
but even high-performing algorithms may select patients in a non-random manner and bias the 
resulting cohort. To improve the efficiency of cohort selection while measuring potential bias, 
we introduce a technique called Model-Assisted Cohort Selection (MACS) with Bias Analysis 
and apply it to the selection of metastatic breast cancer (mBC) patients. 
MATERIALS AND METHODS 
We trained a model on 17,263 patients using term-frequency inverse-document-frequency 
(TF-IDF) and logistic regression. We used a test set of 17,292 patients to measure algorithm 
performance and perform Bias Analysis. We compared the cohort generated by MACS to the 
cohort that would have been generated without MACS as reference standard, first by comparing 
distributions of an extensive set of clinical and demographic variables and then by comparing the 
results of two analyses addressing existing example research questions.  
RESULTS 
Our algorithm had an area under the curve (AUC) of 0.976, a sensitivity of 96.0%, and an 
abstraction efficiency gain of 77.9%. During Bias Analysis, we found no large differences in 
baseline characteristics and no differences in the example analyses. 
CONCLUSION 
MACS with bias analysis can significantly improve the efficiency of cohort selection on EHR 
data while instilling confidence that outcomes research performed on the resulting cohort will 
not be biased. 
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INTRODUCTION 
The widespread adoption of electronic health records (EHRs) by oncology practices in recent 
years has enabled EHRs to become an important source of data for research. Like other types of 
real-world data (RWD), EHR data are generated from routine clinical care and describe broad 
patient populations. In oncology specifically, where the treatment landscape is evolving rapidly, 
the use of deidentified RWD for research provides an opportunity to advance knowledge faster 
than allowed by prospective clinical trials alone. Compared to other RWD sources like registries 
and claims datasets, EHRs offer advantages for research such as longitudinality of data 
collection, recency, generalizability, and depth of clinical information capture.[1] 
Repurposing EHR data for research presents unique challenges but also introduces opportunities 
to use technology to accelerate research. One fundamental challenge is that important 
information is often not organized into a consistent data model but is instead distributed across 
unstructured sources like clinical notes and pathology reports.[1] Due to the complexity of 
oncology records, this process of transitioning unstructured data into structured variables 
currently requires manual chart review by trained human abstractors. Chart review, however, can 
be slow, costly, and lack quality control.[2] To address these obstacles, we have developed a 
technique called technology-enabled abstraction, aimed at increasing the accuracy and efficiency 
with which human abstractors can extract critical data elements from each chart.[1, 3] Even with 
this technique, abstraction remains time intensive. 
One challenge closely related to unstructured data is the selection of research cohorts from EHR 
data, which must be performed according to predefined inclusion and exclusion criteria. Many of 
these criteria, ranging from disease features like histology type to patient characteristics like 
genetic predisposition, are not well-captured in structured data alone. As a result, relying solely 
on structured data for cohort selection can miss patients.[1] While technology-enabled 
abstraction can make the use of unstructured data for cohort selection more efficient, the process 
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does not eliminate the need to review all potentially cohort-eligible patients when creating a new 
research dataset. Therefore, better approaches to performing cohort selection at scale are needed. 
Previous work has explored using machine learning (ML) and rule-based systems, often in 
combination with natural language processing (NLP), for creating cohorts based on EHR data in 
an attempt to decrease the burden of manual chart review (see e.g., [4-6]; for a review, see 
[7-10]). ​While high-performing algorithms are promising, they introduce the risk of selecting 
patients in a non-random manner. This could cause the resulting cohort to be biased, which could 
lead to erroneous research findings.  
Here we introduce a framework called Model-Assisted Cohort Selection (MACS) with Bias 
Analysis to more efficiently identify cohort-eligible patients and to assess the resulting cohort’s 
suitability for research.  With MACS, potentially eligible patients pass through a two-step 
cohort-selection filter (Figure 1). In the first step, a model predicts which patients are eligible for 
cohort inclusion. In the second step, human abstractors manually assess patients deemed 
cohort-eligible by the model for cohort eligibility. Then Bias Analysis compares the cohort 
produced by MACS to a reference cohort in which every inclusion or exclusion decision was 
made by a human abstractor. In addition to standard measures such as sensitivity and specificity, 
this comparison includes the distributions of an extensive set of clinical and demographic 
variables as well as the results of analyses addressing example research questions. 
This paper illustrates MACS with Bias Analysis by applying it to the selection a cohort of 
metastatic breast cancer (mBC) patients. Even though ICD codes exist that could be used to 
identify patients with metastatic disease, these codes have been shown to lack sensitivity 
compared to other methods.[3, 11] Thus, accurately knowing whether a patient has developed 
metastatic disease requires using unstructured data,[1] presenting an opportunity for significant 
efficiency improvement via automation. 
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MATERIALS AND METHODS 
Data Source and Processing 
The data source for this study was the Flatiron Health database, a longitudinal, demographically 
and geographically diverse database derived from EHR data. The cutoff date for this study was 
February 1, 2018. At the time of this study, the database included over 265 cancer clinics (at 
approximately 800 sites of care) in the United States representing more than two million active 
patients available for analysis, the majority of whom are seen in the community oncology setting. 
Institutional Review Board approval was obtained prior to study conduct, and informed patient 
consent was waived.  
Patient-level demographic, clinical, and outcomes data were extracted from the source EHR 
system and include structured data as well as data elements extracted from unstructured data in 
clinical documents. Structured data were aggregated, normalized, and harmonized across clinics. 
Documents were classified into a common set of 24 standard categories. Unstructured data 
elements were then extracted using technology-enabled abstraction.[1, 3] Dates of death were 
obtained from a composite mortality variable.[12] Lines of therapy were constructed based on 
drug order and administration data following oncologist-defined rules.  
Labeled Data Preparation 
To generate labeled data for model training, evaluation, and Bias Analysis, we first identified 
patients with recent activity in the EHR by selecting patients with at least two recorded office 
visits on separate dates after January 1, 2011. We then identified patients with a likely breast 
cancer diagnosis based on the presence of a related ICD code (ICD-9 174.x or 175.x or ICD-10 
C50.x) in their structured records. We sent a random subset of these patients for chart review by 
oncology nurses and tumor registrars, who used our in-house technology-enabled abstraction 
platform [1, 3] to extract a number of variables from the unstructured EHR data, including 
whether each patient had mBC (defined as Stage IV breast cancer or recurrence of early-stage 
breast cancer). We then removed patients whose date of metastatic diagnosis was prior to 
January 1, 2011. We did this to avoid introducing immortal time bias caused by the requirement 
of having a visit after that date. 
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 This process resulted in a set of 34,555 patients. We randomly selected 50% of these patients for 
model training (N = 17,263) and reserved the remainder (N = 17,292) as a test set for assessing 
model performance and evaluating the presence of bias caused by using MACS.  
Modeling approach 
Labels 
We assigned a binary label to each patient in the training and test sets: ​positive​ patients were 
those patients who had a diagnosis of mBC, and ​negative​ patients were those who did not have a 
diagnosis of mBC. Because all patients in this dataset had an ICD code indicating a diagnosis of 
breast cancer, most of the negative patients had (non-metastatic) breast cancer. Positive patients 
accounted for approximately 8.5%–9% of cases in both the training and test sets (Table 1). 
Table 1: Number of positive and negative patients in the training and test sets 
 
Positive patients  
(patients with a chart-confirmed 
mBC diagnosis after 1/1/2011) 
Negative patients  
(patients without evidence of mBC 
diagnosis based on chart review) 
Test set 1485 15807 
Training set 1473 15790 
 
 
Feature generation 
The input to our model was a vector of features derived from unstructured EHR data. We first 
selected all documents matching four relevant categories: visit notes, pathology reports, 
procedure and operative reports, and radiology reports. Second, for each patient, we sorted these 
documents chronologically and concatenated them into a single block of text. Third, we removed 
special characters and tokenized the text on white space. Fourth, we extracted unigrams and 
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bigrams from this normalized text and weighted them using term-frequency 
inverse-document-frequency (TF-IDF). Finally, we retained only the 100,000 most commonly 
occurring features for model training efficiency. In our experiments using cross-validation on the 
training data, performance did not increase noticeably when including more features. 
Training 
We randomly selected 80% of our training data and used the labels and features described above 
to train a logistic regression model. This model used L2-regularization, where the regularization 
constant was selected to maximize the area under the receiver operating characteristic (ROC) 
curve during cross-validation on this subset of the training data. We performed feature 
generation and training using the scikit-learn library.[13] 
Choosing a score threshold 
The trained logistic regression model outputs a score between 0 and 1 for each patient; a higher 
score indicates increased confidence that the patient is metastatic. In order to turn this into a 
binary classifier, a threshold must be chosen such that patients will be classified as metastatic if 
and only if the model outputs a score higher than this threshold. Using a validation set consisting 
of the remaining 20% of the training data, we selected a score threshold predicted to give 95% 
sensitivity. More precisely, we chose the largest value ​x​ such that at least 95% of the positive 
examples in the validation set had a score higher than ​x​. We chose this high value for the target 
sensitivity to reduce the potential for introducing bias. 
Analysis  
Model performance 
We assessed performance of the model on the test set by plotting the ROC curve, measuring the 
area under this curve (AUC), as well as the sensitivity and abstraction efficiency gain of the 
model with the chosen threshold. We defined abstraction efficiency gain to be the fraction of 
patients excluded from manual abstraction in the second step of MACS because their scores fell 
below the threshold. Although we chose a threshold to achieve a certain sensitivity, it is still 
important to measure sensitivity on the test set to ensure that the chosen threshold generalizes to 
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new data. Confidence intervals for sensitivity and abstraction efficiency were generated based on 
1000 bootstrapped samples. 
Bias Analysis 
To assess whether using MACS introduced bias, we used the set of all positive patients in the test 
set as a Reference Standard. Because every patient in the test set was manually abstracted to 
determine metastatic status, the Reference Standard represents the cohort that would have been 
generated without using MACS. We compared the Reference Standard to the subset of these 
patients classified as positive by the model. This latter set of patients, called the MACS Cohort, 
represents the cohort that would have been generated by the MACS process. We used these 
cohorts to assess MACS for bias using the following two approaches. 
First, we compared baseline demographic and clinical distributions in the MACS Cohort to the 
corresponding distributions in the Reference Standard. We summarized a number of 
demographic and clinical characteristics within the two cohorts using descriptive statistics 
(medians and interquartile ranges (IQR) for continuous variables and percentages for categorical 
variables). For each measure of interest, we calculated the difference between the two cohorts 
and obtained 95% empirical confidence intervals (CIs) using the percentile method by drawing 
1000 bootstrap samples with replacement equal in size to the two original cohorts. 
Our second approach compared the results of analyses addressing existing example research 
questions on the MACS Cohort to the corresponding results of analyses on the Reference 
Standard. The rationale for this approach was that if the MACS Cohort is unbiased, results from 
any analysis conducted in the Reference Standard should be replicable in the MACS Cohort. The 
example analyses were chosen to be representative of the types of analyses that will ultimately 
be conducted on the cohort. In this work, we illustrate the idea with two basic outcomes 
analyses: (1) What is the median overall survival (OS) following diagnosis with mBC, and (2) 
how does OS vary by hormone receptor (HR) and human epidermal growth factor receptor 2 
(HER2) status at the time of mBC diagnosis? HR status is defined as negative if the tumor is 
found to express neither progesterone receptors (PRs) nor estrogen receptors (ERs) and defined 
as positive for any other finding. HR and HER2 status are important prognostic factors in mBC 
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and inform treatment decisions. We specifically compared OS in patients with negative HR and 
negative HER2 status (triple negative) to OS in patients with positive HR status and negative 
HER2 status (HR+/HER2-) as triple negative breast cancer is known to have worse outcomes 
than HR+/HER2- breast cancer. [14] We extracted HR and HER2 status at the time of metastatic 
diagnosis via technology-enabled chart abstraction of relevant information.  1
We performed survival analyses using standard Kaplan-Meier methods [15]. We defined the 
index date to be the date of a patient’s metastatic diagnosis and the event date to be the date of 
death due to any cause. We censored patients who were lost to follow-up or had not yet 
experienced the relevant event by the end of the study period at the date of last confirmed 
activity (last clinical visit or drug administration date). We calculated medians, 95% CIs, and 
Kaplan-Meier curves for each outcome. For each comparison we further calculated the 
difference in median OS between the MACS Cohort and the Reference Standard, computing 
95% empirical CIs for the difference with the bootstrapping method described above. In the 
analysis of OS by HR and HER2 status we further compared OS between mBC subpopulations 
(HR+/HER2- vs. triple negative) within the same cohort (Reference Standard or MACS Cohort) 
for statistically significant differences using log rank tests. 
  
1 We identified ER, PR, and HER2 status at time of metastatic diagnosis as follows: the closest successful test within 60 days of 
metastatic diagnosis date or when no such test is available, the closest successful test before metastatic diagnosis date. When only 
tests with pending, inconclusive, or unknown results were available, we applied the same date criteria to select the most relevant 
test. Patients were considered to be HR+ if they had either a positive ER or a positive PR status based on the above definition 
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RESULTS 
Model performance 
Our logistic regression model for predicting whether a patient was diagnosed with mBC had an 
AUC on our held out test data of 0.976 (95% CI: 0.973, 0.979). The ROC curve of the model is 
shown in Figure 2. The score threshold chosen to achieve 95% sensitivity during model training 
was 0.047. Sensitivity in the test set was 96.0% (95% CI: 94.9, 96.9), indicating that the 
threshold chosen during model training generalized well. The abstraction efficiency gain for the 
chosen threshold was 77.9% (95% CI: 77.2, 78.5). This means that the model reduced the 
number of charts needing human review by 78% while missing 4% of the positive patients 
(Table 2). 
Table 2: comparison of cohort selection using a standard technology-enabled abstraction 
approach vs MACS. 
 
Standard 
approach 
MACS Difference Decrease due to MACS 
Patients abstracted 17292 3827 13465 77.87% 
Patients in resulting cohort 1485 1425 60 4.04% 
 
Bias Analysis 
Distribution of demographic and clinical characteristics 
We compared distributions of demographic and clinical baseline characteristics to assess if 
missing 4% of patients through MACS results in meaningful changes that could bias the results 
of downstream analyses. Table 3 shows the comparison of demographic and clinical 
characteristics between the Reference Standard and the MACS Cohort. Overall, differences 
between the two cohorts were small; for example, median age at initial and metastatic diagnosis 
and median follow-up time differed by less than a year between the two cohorts. For all 
measured categorical variables and levels, the observed differences between the two cohorts 
10 
 
were less than 1% and the upper and lower bounds suggested by the 95% CIs were all less than 
4%. Qualitatively, the biggest differences were observed in the year of metastatic diagnosis date, 
with the MACS cohort showing a small shift towards earlier diagnosis dates, and in the stage at 
primary breast cancer diagnosis, with the MACS cohort showing a shift toward Stage IV. 
Table 3: Comparison of demographic and clinical baseline characteristics. The rightmost 
column shows the difference between the Reference Standard and the MACS Cohort (in percent 
for categorical variables and medians for continuous variables). 
 
Ref. Standard  
(N = 1485) 
MACS Cohort (N 
= 1425) 
Ref. Standard - 
MACS Cohort [CI] 
Demographics 
Median age at primary breast 
cancer diagnosis, years [IQR] 59 [50, 68] 59 [50, 68] 0 [-2, 1] 
Age at primary breast cancer diagnosis category, n [%] 
  19-34 47 [3.16] 47 [3.3] -0.13 [-1.04, 1.36] 
  35-50 317 [21.35] 308 [21.61] -0.27 [-2.74, 3.33] 
  50-64 595 [40.07] 575 [40.35] -0.28 [-3.43, 3.79] 
  65-74 313 [21.08] 292 [20.49] 0.59 [-3.53, 2.49] 
  75+ 200 [13.47] 191 [13.40] 0.06 [-2.63, 2.23] 
  Unknown 13 [0.88] 12 [0.84] 0.03 [-0.72, 0.59] 
Median age at mBC diagnosis, 
years [IQR] 64 [55, 73] 64 [55, 73] 0 [-2, 1] 
Age at mBC diagnosis category, n [%] 
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  19-34 24 [1.62] 24 [1.68] -0.07 [-0.82, 1.03] 
  35-50 190 [12.79] 184 [12.91] -0.12 [-2.23, 2.45] 
  50-64 541 [36.43] 524 [36.77] -0.34 [-2.99, 3.62] 
  65-74 394 [26.53] 375 [26.32] 0.22 [-3.41, 2.85] 
  75+ 336 [22.63] 318 [22.32] 0.31 [-3.33, 2.58] 
Gender, n [%] 
  Female 1474 [99.26] 1415 [99.30] -0.04 [-0.52, 0.65] 
  Male 11 [0.74] 10 [0.70] 0.04 [-0.65, 0.52] 
Race/ethnicity, n [%]   
  White 958 [64.51] 915 [64.21] 0.3 [-3.64, 3.42] 
  Black or African American 171 [11.52] 164 [11.51] 0.01 [-2.39, 2.34] 
  Asian 46 [3.10] 46 [3.23] -0.13 [-1.11, 1.37] 
  Other race 169 [11.38] 166 [11.65] -0.27 [-2.09, 2.46] 
  Unknown 141 [9.49] 134 [9.40] 0.09 [-2.37, 1.84] 
Practice type, n [%] 
  Academic 99 [6.67] 89 [6.25] 0.42 [-2.06, 1.35] 
  Community 1386 [93.33] 1336 [93.75] -0.42 [-1.35, 2.06] 
Clinical characteristics 
Stage at primary breast cancer diagnosis, n [%] 
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  0 < 5 < 5 0 [-0.2, 0.21] 
  I 136 [9.16] 127 [8.91] 0.25 [-2.07, 1.83] 
  II 356 [23.97] 334 [23.44] 0.53 [-3.52, 2.72]  
  III 311 [20.94] 297 [20.84] 0.1 [-2.94, 2.98] 
  IV 461 [31.04] 452 [31.72] -0.68 [-2.66, 4.14] 
  Not documented 220 [14.81] 214 [15.02] -0.2 [-2.26, 2.68] 
HR status at mBC diagnosis, n [%]  
  Positive 1117 [75.22] 1073 [75.30] -0.08 [-3.28, 3.16] 
  Negative 310 [20.88] 296 [20.77] 0.1 [-3.08, 3.08] 
  Results unknown/not assessed 58 [3.91] 56 [3.93] -0.02 [-1.36, 1.53] 
HER2 status at mBC diagnosis, n [%] 
  Positive 239 [16.09] 230 [16.14] -0.05 [-2.56, 2.57] 
  Negative 1066 [71.78] 1022 [71.72] 0.07 [-3.59, 3.63] 
  Equivocal 90 [6.06] 86 [6.04] 0.03 [-1.65, 1.61] 
  Results unknown/not assessed 90 [6.06] 87 [6.11] -0.04 [-1.68, 1.84] 
BRCA status (germline), n [%]  
  Positive 45 [3.03] 44 [3.09] -0.06 [-1.11, 1.25] 
  Negative 270 [18.18] 260 [18.25] -0.06 [-2.79, 2.9] 
  Other result 9 [0.61] 9 [0.63] -0.03 [-0.53, 0.57] 
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  Results unknown/not assessed 1161 [78.18] 1112 [78.04] 0.15 [-3.4, 2.69] 
Median number of visits [IQR] 37 [15, 72] 37 [15, 72] 0 [-2, 4] 
Median number of lines of 
therapy [IQR] 1 [1, 3] 2 [1, 3] -1 [-1, 1] 
Median follow-up time from 
mBC diagnosis, months [IQR] 16.23 [6.07, 34.07] 16.77 [6.07, 34.07] -0.53 [-1.07, 2.07] 
Year of mBC diagnosis, n [%] 
  2011 167 [11.25] 165 [11.58] -0.33 [-1.88, 2.74] 
  2012 204 [13.74] 199 [13.96] -0.23 [-2.51, 2.77] 
  2013 209 [14.07] 204 [14.32] -0.24 [-2.2, 2.66] 
  2014 255 [17.17] 251 [17.61] -0.44 [-2.32, 3.32] 
  2015 263 [17.71] 252 [17.68] 0.03 [-2.94, 2.64] 
  2016 233 [15.69] 216 [15.16] 0.53 [-3.09, 2.2] 
  2017 149 [10.03] 133 [9.33] 0.7 [-2.85, 1.32] 
  2018 5 [0.34] 5 [0.35] -0.01 [-0.4, 0.43] 
 
 
Effect on example research questions 
In the first analysis, we assessed OS from the date of mBC diagnosis in the two cohorts (Figure 
3). Among the 1485 patients in the Reference Standard there were a total of 751 patients with 
recorded all-cause death events compared to 731 such patients recorded among the 1425 patients 
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in the MACS Cohort. The estimated median OS was 2.71 years (95% CI: 2.51, 2.93) in the 
Reference Standard and 2.72 years (95% CI: 2.52, 2.96) in the MACS cohort (difference in 
median OS: -0.01 years; 95% CI: -0.31, 0.30). 
For the second analysis, we compared OS as a function of HR and HER2 status (triple negative 
vs. HR+/HER2-) to test if there is bias in the MACS Cohort that becomes apparent when 
addressing research questions in smaller cohorts (Figure 4). In the Reference Standard, the 
estimated median OS was 3.03 years (95% CI: 2.76, 3.27) for HR+/HER2- patients compared to 
1.16 years (95% CI: 0.86, 1.39) for patients with triple negative breast cancer. In line with 
clinical expectations, the difference in median OS between the two subpopulations was 
statistically significant (log-rank p-value < 0.001). This difference in OS was replicated in the 
MACS Cohort (HR+/HER2-: 3.08 years, 95% CI: 2.78, 3.28; triple negative: 1.17 years, 95% 
CI: 0.86, 1.42; log-rank p-value < 0.001). The direct comparison of median OS for the two 
subpopulations between the Reference Standard and the MACS Cohort showed that the 
differences between the two cohorts were again clinically not meaningful. The difference in 
median OS among patients with HR+/HER2- mBC was -0.04 years (95% CI: -0.31, 0.30) and 
among patients with triple negative mBC was -0.02 years (95% CI: -0.39, 0.36). 
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DISCUSSION 
EHRs are a promising source of RWD for health outcomes research, but selecting targeted 
cohorts of oncology patients often requires the use of information that is captured only in 
unstructured parts of the record. In cases where research draws on these unstructured sources, 
human review of each chart has traditionally been needed, but this makes studies labor intensive 
and slow to perform on large populations. 
To address the need for more efficient cohort selection for building deidentified EHR-based 
research datasets, we developed MACS, a technique that uses ML to filter out patients who are 
unlikely to be part of a cohort. Here, we applied MACS to the example of mBC and showed that 
it can reduce the number of charts needing human review by 78% while missing only 4% of 
cohort-eligible patients. 
In this work, we have advanced the methods previously developed for automating cohort 
selection by supplementing traditional performance measures such as sensitivity and AUC with a 
thorough examination for bias. To perform this bias analysis, we compared the MACS Cohort to 
a reference standard cohort that was built using human review of each chart. First, we compared 
baseline clinical and demographic characteristics and found no large differences. Second, we 
compared the analyses of example research questions and showed that the findings did not 
depend on which cohort was used. This bias analysis step instilled confidence that the ML model 
did not systematically miss patients in a way that introduced clinically meaningful bias. 
Notably, although MACS with Bias Analysis can automate a significant amount of cost and 
effort, it still requires the manual abstraction of unstructured data. For MACS, this abstraction is 
needed to produce the ground-truth labels for training and testing; for bias analysis, it is needed 
to extract many of the patient-level variables included in the baseline comparisons of cohorts and 
example analyses. Thus, even though MACS with Bias Analysis can rapidly scale cohort 
selection, it is built on a foundation of human expertise and on the technology to leverage that 
expertise at scale. Over time, we expect that automated methods will continue to reduce the 
manual work required for expert data curation, but this must be done carefully to ensure that 
quality is maintained when the downstream datasets are used for research. 
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 The amount of bias that is permissible depends on how the data are being used, requiring some 
clinical and statistical judgement. When bias is deemed too great, there are at least two options 
that can be pursued. First, the score threshold can be adjusted to increase the sensitivity of the 
model. While this will not change the bias inherent in the algorithm, it means that fewer patients 
will be excluded, and therefore the magnitude of the bias will likely be reduced. Second, the 
training algorithm can be modified to address the bias directly (as long as when bias is 
reassessed, it is done on fresh test data). For example, higher weights can be given to patients 
belonging to a subpopulation that the bias analysis indicates would be systematically excluded 
otherwise. 
Abstractors trained to do manual curation are a constrained resource. As shown here, MACS can 
significantly reduce the time and cost to create deidentified research datasets based on EHR data. 
With the savings from techniques like MACS, we can reallocate resources to other high-value 
abstraction tasks and to scaling research datasets in other disease areas. Thus, the ultimate benefit 
of MACS is that it allows for an increase in the amount and scope of research that can be done 
with EHR data. 
Limitations 
A limitation of our work is that our methods for bias analysis do not fully preclude the possibility 
of bias entering into the cohort. First, we can assess bias only for variables that are captured in 
the dataset. Second, even for those variables, bias may be apparent only when the joint 
distribution of a subset of variables is examined, and we cannot examine every possible subset. 
Similarly, we cannot test every example research question. Finally, the use of the reference 
standard cohort to assess bias may mask bias that already exists in the reference standard itself. 
Ultimately, our method for bias analysis relies on clinical judgement to choose variables and 
example analyses that will sufficiently raise confidence in the representativeness of the resulting 
data set. 
Another limitation is that our method for generating a reference standard is inefficient when the 
target population has a low prevalence since we rely on randomly sampling patients of potential 
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interest. Many patients would need to be abstracted to create a reference standard of sufficient 
size. In our example of mBC, the prevalence was 9%, which meant finding the 1485 patients for 
our reference standard required abstracting charts for over 15,000 patients. For a target 
population with a substantially lower prevalence, this approach to building a reference standard 
may become infeasible. 
A final limitation is that our implementation of MACS for mBC had a somewhat decreased 
sensitivity for patients who were diagnosed with breast cancer at an early stage or who became 
metastatic only recently (Table 3). A reason for this may be that our approach used a linear 
model that does not include any representation of the longitudinality of the input EHR. This 
limitation could be addressed by exploring a non-linear model or by modeling time more 
directly. We left this for future work because overall, the differences in baseline distributions 
were small. 
Future work 
The use of MACS outlined here was for one-time cohort selection, but MACS can also support 
EHR-based registries when applied longitudinally. Such applications face the challenge of 
evolving data inputs. For example, the contents of the EHR for an individual patient will grow as 
that patient continues to receive care, and the population-level distribution of variables may shift 
as the underlying database grows or shrinks, documentation patterns change, and standards of 
care evolve. In such situations, both the training and test sets must be grown continuously to 
remain representative, and new models must be periodically deployed. 
MACS can also be used to identify research cohorts beyond mBC. Within oncology, it can be 
applied to identify patients who have particular biomarkers, who have received a specific 
therapy, or who have advanced or metastatic disease in other tumor types. Beyond oncology, 
similar approaches can be applied to generate research cohorts in a wide variety of disease states. 
In general, MACS can improve the efficiency of cohort selection in situations where 
unstructured data is required and when patients who satisfy the cohort inclusion and exclusion 
criteria are relatively rare, as long as sufficient labeled data is available and the model’s 
performance and potential for introducing bias are monitored. 
18 
 
CONCLUSION 
This work shows how combining automated ML approaches with technology-enabled 
abstraction and rigorous validation analyses offers a powerful method for overcoming some of 
the challenges of using large-scale EHR data for research. Applying MACS with Bias Analysis, 
it is possible to perform cohort selection for EHRs more efficiently while still preserving 
confidence in data quality, allowing for the acceleration of outcomes research using EHR data. 
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FIGURES 
Figure 1. Schema of MACS with Bias Analysis. A. Two-step MACS cohort-selection process: in 
the first step, a model predicts which patients are eligible for cohort inclusion. In the second step, 
human abstractors manually assess patients deemed cohort-eligible by the model for cohort 
eligibility. B. Bias Analysis compares the cohort produced by MACS to a reference cohort in 
which every inclusion or exclusion decision was made by a human abstractor. 
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Figure 2. ROC curve of the logistic regression model used in MACS (AUC: 0.976, 95% CI: 
0.973, 0.979). 
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 Figure 3.  Kaplan-Meier estimates of OS from the date of mBC diagnosis. A. Reference 
Standard. B. MACS Cohort. 
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Figure 4. Kaplan-Meier estimates of OS as a function of HR and HER2 status (triple negative vs. 
HR+/HER2- subgroups). A. Reference Standard. B. MACS Cohort. 
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